AbbVie (ABBV) Equity Average (2013 - 2026)

AbbVie (ABBV) has 14 years of Equity Average data on file, last reported at -$5.0 billion in Q1 2026.

• Equity Average for Q1 2026 came in at -$5.0 billion, down 305.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.0 billion (down 305.68% YoY), and the FY2025 annual result was $47.0 million, down 99.32% from the prior year.
• Equity Average eased to -$5.0 billion in Q1 2026 per ABBV's latest filing, from -$3.0 billion in the prior quarter.
• Over five years, Equity Average peaked at $16.7 billion in Q4 2022 and troughed at -$5.0 billion in Q1 2026.
• A 5-year average of $8.1 billion and a median of $9.2 billion in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2026: Equity Average gained 18.34% in 2022, then sank 305.68% in 2026.
• A 5-year view of Equity Average shows it stood at $16.7 billion in 2022, then plunged by 32.38% to $11.3 billion in 2023, then slumped by 58.12% to $4.7 billion in 2024, then tumbled by 162.66% to -$3.0 billion in 2025, then sank by 67.9% to -$5.0 billion in 2026.
• Business Quant data shows ABBV's Equity Average at -$5.0 billion in Q1 2026, -$3.0 billion in Q4 2025, and -$1.4 billion in Q3 2025.